• Home
    • StockRanks™
    • Platform
        • Research & Discuss
        • Editorial & Community
        • Learn & Improve
        • Webinars & Masterclasses
        • Stockopedia Academy
    • Reviews
    • Pricing
    Get startedLog in
    SectorsHealthcareBiotechnology & Medical ResearchImmatics
    Picture of Immatics logo

    IMTX — Immatics News Story

    $7.540.000.00%
    us flag iconLast trade - 00:00
    HealthcareAdventurousMid CapSucker Stock
    • Market Cap
      $1.15bn
    • Enterprise Value
      $723.05m
    • Revenue
      €48.27m
    • Quality
    • Value
    • Momentum
    • StockRank™
    • StockReport™
    • Accounts
      • Balance sheet
      • Income statement
      • Cashflow statement
      • Dividend summary
    • News
    • IMTX Dividends
    StockReport™
    Balance sheet
    Income statement
    Cashflow
    News
    IMTX Dividends
    All News

    NASDAQ RESUMED

    Picture of Immatics logoImmatics
    12/12/2018 16:11
    NASDAQ RESUMED  ARYA.O
    

    Recent news on Immatics

    See all news
    • Immatics up after deal with Moderna to develop cancer vaccines

      11/09/2023 12:45
    • U.S. RESEARCH ROUNDUP- Agrify, Okta, Schnitzer Steel Industries

      24/03/2022 07:14
    • Brief: Immatics NV Says Company Projects A Cash Runway Into 2024

      23/03/2022 11:10
    • Bristol Myers enters up to $920 mln deal with Immatics for cancer drug

      14/12/2021 12:00
    • Brief: Immatics And Bristol Myers Squibb Enter Into Global Exclusive License For Immatics’ TCR Bispecific Program Ima401

      14/12/2021 11:59

    Company

    • About us
    • Careers
    • Product Guide

    Our Coverage

    • Countries
    • Sectors
    • Ratios

    Top Stocks

    • UK Stocks
    • Australian Stocks
    • US Stocks

    Legals

    • Privacy Policy
    • Terms & Conditions
    • Disclaimer & FSG
    • Cookies
    Trustpilot
    Select a country/region:


    © Stockopedia 2026, Refinitiv, Share Data Services.

    *Past performance is no indicator of future performance, and testimonials are provided by third parties for informational purposes only and are not intended and should not be taken to be financial product advice. Performance returns are based on hypothetical scenarios and do not represent an actual investment.

    This site cannot substitute for professional investment advice or independent factual verification. To use Stockopedia, you must accept our Terms of use, Privacy and Disclaimer & FSG. All services are provided by Stockopedia Ltd, United Kingdom (company number 06367267). For Australian users: Stockopedia Ltd, ABN 39 757 874 670 is a Corporate Authorised Representative of Daylight Financial Group Pty Ltd ABN 77 633 984 773, AFSL 521404.